Mirvetuximab soravtansine: Phase III amended

ImmunoGen said it changed the design of the ongoing FORWARD I trial comparing IV mirvetuximab soravtansine as a single agent vs. investigator’s choice chemotherapy.

Read the full 248 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE